



JC10 Rec'd PCT/PTO 21 JUL 2005

PATENT

Atty. Docket: 0100024/0532135

#3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Peter R. Chang et al.

: Paper No:

Serial No. 10/528,877

: Group Art Unit:

Filed:

: Examiner:

For: EXTRACTION, PURIFICATION AND CONVERSION OF FLAVONOIDS FROM
PLANT BIOMASS

INFORMATION DISCLOSURE STATEMENT

Mail Stop AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, Applicant herewith submits certain patent references and other information, which the Patent & Trademark Office may wish to consider in examining the above-identified application. The references are listed below, and are also listed on the attached Form PTO-1449.

U.S. Patent Documents	Publication Date	Patentee/Applicant
US- 3,382,475	08-28-1974	Zirlin
US- 5,122,381	06-16-1992	Nishimura et al.
US- 5,145,781	09-08-1992	Suzuki et al.
US- 5,565,435	10-15-1996	Yoneyama et al.

Foreign Patent Documents	Publication Date	Patentee/Applicant
WO 00-026400	05-11-2000	Merck Patent GmbH
WO 01-51482	07-19-2001	Biorex Health Ltd.
WO 01-59143	08-16-2001	Merck Patent GmbH
CN 1160048	09-24-1997	Zhai Guangyu
EP 0 387 042	02-15-1995	Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo
EP 0 420 376	03-13-1996	"
JP 6128142	05-10-1994	Kose Corp.
JP 02073079	03-13-1990	Daicel Chemical

JP 04066096	03-02-1992	San-Ei Kagaku Kogyo
JP 04066098	03-02-1992	San-Ei Kagaku Kogyo
JP 6014746	01-25-1994	Omiya Yakugyo; Ito Midori
JP 6248267	09-06-1994	SII Techno Res Yugen; Nakayama Tsutomu
JP 07324037	12-12-1995	Nippon Getsuto
JP 9094077	04-08-1997	San Ei Gen FFI Inc.
DE 4107079	09-10-1992	Merck
DE 4339486	05-24-1995	Backhaus
DE 4340438	06-01-1995	Backhaus
SU 904709	02-15-1982	Sechnov, I.M. Medical Institute
CN 1160048	09-24-1997	Peopl. Rep. China
CN 1217329	05-26-1999	Huo Xingling

Non Patent Literature Documents

- GRIFFITH, JR., J. et al., Effect of rutin on increased capillary fragility in man, Proc. Soc. Exptl. Biol. Med., 1944, vol. 55, pp 228-229
- HUMPHREYS, F.R., The occurrence and industrial production of rutin in southeastern Australia, Economic Botany, 1964, vol. 18, 195-253
- GRIFFITHS, L.A. & BARROW, A., Metabolism of flavonoid compounds in germ-free rats, Biochem. J., 1972, vol. 130, pp 1161-1162
- UYETA, M., et al., Mutagenicity of hydrolysates of tea infusions, Mutation Research, 1981, vol. 88, pp 233-240
- BASARKAR, P.W. & NATH, N., Cholesterol lowering action of vitamin P-like compounds in rats, Indian Journal of Experimental Biology, Aug. 1981, vol. 19, pp 787-789
- KATO, N., et al., Effects of dietary quercetin on serum lipids, Agric. Biol. Chem., 1983, vol. 47, no. 9, 2119-2120
- PROCHAZKA, V., Can wild buckwheat be a commercial source, Naše Liečivé Rastliny, 1985, vol. 22, pt. 5, pp 131-133
- MATSUBARA, Y., et al., Structure and Hypotensive Effect of Flavonoid Glycosides in *Citrus unshiu* peelings, Agric. Biol. chem., 1985, vol. 49, no. 4, pp 909-914
- BORS, W., et al., [36] Flavonoids as antioxidants, Methods in Enzymology, 1990, vol. 186, pp 343-355, Academic Press
- HAYASHIBARA BIOCHEMICAL LABORATORIES INC., Water soluble rutin functioning as vitamin P, Japan Report Medical Technology, Feb. 1990, vol. 4, no. 2,
- HAYASHIBARA BIOCHEMICAL LABORATORIES INC., Water soluble rutin, New Technology and Products, JETRO, Feb. 1990, p. 34
- IWATA, K., et al., Effects of kangra buckwheat on spontaneously hypertensive rats, 1990, vol. 21, pp 55-61
- YILDIZOĞLU-ARI, N., et al. Pharmacological effects of rutin, Phytotherapy Research, 1991, vol. 5, no. 1, pp 19-23
- ABOU-KARAM, M. & SHIER, W., Isolation and characterization of an antiviral flavonoid from *Waldsteinia fragarioides*, Journal of Natural Products, Oct. 1992, vol. 55, no. 10, pp 1525-1527
- DESCHNER, E., Dietary quercetin and rutin, inhibitors of experimental colonic neoplasia, Ch. 19, Phenolic Compounds in Food and Their Effects on Health II, 1992, ACS Symposium Series 507, American Chemical Society, Washington, DC

- LUTTERODT, G.D. & ABU RAIHAN, S.M., Calcium modulation and antinociceptive efficacy of quercetin compounds, *Asia Pacific Journal of Pharmacology*, 1993, vol. 8, pp 127-131
-
- AGULLO, G., et al., Quercetin exerts a preferential cytotoxic effect on active dividing colon carcinoma HT29 and Caco-2 cells, *Cancer Letters*, 1994, vol. 87, pp 55-63
-
- MIDDLETON, JR., E. & KANDASWAMI, C, The impact of plant flavonoids on mammalian biology: implications for immunity, inflammation and cancer, *The Flavonoids: Advances in Research Since 1986*, Harborne, J.B., ed., 1994, Ch. 15, pp 619-652, Chapman & Hall, London
-
- PISHA, E. & PEZZUTO, J., Fruits and vegetables containing compounds that demonstrate pharmacological activity in humans, *Economic and Medicinal Plant Research*, 1994, vol. 6, pp 189-233, Wagner & Farnsworth, ed., Academic Press, London
-
- OOMAH, D & MAZZA, G., Flavonoids and antioxidative activities in buckwheat, *J. Agri. Food Chem.*, 1996, vol. 44, no. 7, pp 1746-1750
-
- MANACH, C., Bioavailability, metabolism and physiological impact of 4-oxo-flavonoids, *Nutrition Research*, 1996, vol. 16, no. 3, pp 517-544
-
- FERRY, D., et al., Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for *in vivo* tyrosine kinase inhibition, *Clinical Cancer Research*, April 1996, vol. 2, pp 659-668
-
- AGULLO, G., et al., Relationship between flavonoid structure and inhibition of phosphatidylinositol 3-kinase: a comparison with tyrosine kinase and protein kinase C inhibition, *Biochemical Pharmacology*, 1997, vol. 53, pp 1649-1657
-
- WATANABE, J., et al., Isolation and identification of α -glucosidase inhibitors from tochu-cha (*Eucommia almoides*), *Biosci. Biotech. Biochem.*, 1997, vol. 1, no. 1, pp 177-178
-
- MANACH, C., et al., Quercetin is recovered in human plasma as conjugated derivatives which retain antioxidant properties, *FEBS Letters*, 1998, vol. 426, pp 331-336
-
- MINAMI, M., et al., Quantitative analysis of rutin in buckwheat (*Fagopyrum* sp.) by high performance liquid chromatography, *Journal of the faculty of agriculture*, 1998, vol. 34, no. 2, pp 91-95, Shinshu University, Minamiminowa, Nagano, Japan
-
- MORAND, C., et al., Plasma metabolites of quercetin and their antioxidant properties, *Am J. Physiol.*, 1998, vol. 275, pp R212-R219
-
- NOROOZI, M., et al., Effects of flavonoids and vitamin C on oxidative DNA damage to human lymphocytes¹⁻³, *Am. J. Clin. Nutr.*, 1998, vol. 67, pp 1210-1218
-
- CRESPY, V., et al., Part of quercetin absorbed in the small intestine is conjugated and further secreted in the intestinal lumen, *Am. J. Physiol.* 1999, vol. 277, pp G120-G126
-
- ASHIDA, H., et al., Flavones and flavonols at dietary levels inhibit a transformation of aryl hydrocarbon receptor induced by dioxin, *FEBS Letters*, 2000, vol. 476, pp 213-217
-
- BORRELLI, F. & IZZO, A., The plant kingdom as a source of anti-ulcer remedies, *Phytother. Res.*, 2000, vol. 14, pp 581-591
-
- CALTAGIRONE, S., ET AL., Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential, *Int. J. Cancer*, 2000, vol. 87, 595-600
-
- GEE, J., et al., Intestinal transport of quercetin glycosides in rats involves both deglycosylation and interaction with the hexose transport pathway, *J. Nutri.*, 2000, vol. 130, pp 2765-2771

MORAND, C., et al., Quercetin 3-O- β -glucoside is better absorbed than other quercetin forms and is not present in rat plasma, *Free Rad. Res.*, 2000, vol. 33, pp 667-676

SKIBOLA, C & SMITH, M., Potential health impacts of excessive flavonoid intake, *Free Radical Biology & Medicine*, 2000, vol. 29, nos. 3-4, pp 376-383

SLOLEY, B., et al., Chemical and pharmacological evaluation of *Hypericum perforatum* extracts, *Acta Pharmacol Sin*, Dec. 2000, vol. 21, no. 12, pp 1145-1152

WANG, H., The therapeutic potential of flavonoids, *Exp. Opin. Invest. Drugs*, 2000, vol. 9, no. 9, pp 2103-2119

YEŞİLADA, E., et al., Isolation and characterization of free radical scavenging flavonoid glycosides from the flowers of *Spartum junceum* by activity-guided fractionation, *Journal of Ethnopharmacology*, 2000, vol. 73, pp 471-478

ISHIGE, K., et al., Flavonoids protect neuronal cells from oxidative stress by three distinct mechanisms, *Free Radical Biology & Medicine*, 2001, vol. 30, no. 4, pp 433-446

VALERIO, L.G., et al., Induction of human NAD(P)H:quinone oxidoreductase (NQO1) gene expression by the flavonol quercetin, *Toxicology Letters*, 2001, vol. 119, pp 49-57

Copies are provided of foreign patent reference and non-patent literature documents. A copy of the International Search Report from corresponding PCT Application PCT/CA03/01453 is enclosed for the Examiner's convenience. No representation is made or intended that a prior art search has been made or that no better art than the listed is available. It is respectfully requested that the information be considered by the Examiner and made of record in the present application.

CERTIFICATE OF MAILING


I hereby certify that a copy of this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

July 18, 2005
Sarah Abraham
Sarah Abraham

18 July, 2005

Respectfully submitted,

Peter R. Chang et al.


Steven J. Goldstein
Registration No. 28,079

FROST BROWN TODD LLC
2200 PNC Center
201 East Fifth Street
Cincinnati, Ohio 45202-4182
Telephone (513) 651-6131

Substitute for Form PTO 1449

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application No.	10/528,877
Filing Date	
First Named Inventor	Chang, Peter R.
Art Unit	
Examiner Name	
Attorney Docket No.	0100024/0532135

U.S. PATENT DOCUMENTS

Examiner initials	Cite No.	DOCUMENT NUMBER	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind code ² (if known)			
		US- 3,382,475	08-28-1974	Zirlin	
		US- 5,122,381	06-16-1992	Nishimura et al.	
		US- 5,145,781	09-08-1992	Suzuki et al.	
		US- 5,565,435	10-15-1996	Yoneyama et al.	

FOREIGN PATENT DOCUMENTS

Examiner initials	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind code ⁵ (if known)				
		WO 00-026400	05-11-2000	Merck Patent GmbH	p. p 13-15	✓
		WO 01-51482	07-19-2001	Biorex Health Ltd.	p. 6, claim 27	
		WO 01-59143	08-16-2001	Merck Patent GmbH	p. 3, 8, 30, claims 1-4	✓
		CN 1160048	09-24-1997	Zhai Guangyu		Ab.
		EP 0 387 042	02-15-1995	Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo		
		EP 0 420 376	03-13-1996	"		
		JP 6128142	05-10-1994	Kose Corp.		Ab.
		JP 02073079	03-13-1990	Daicel Chemical		Ab.
		JP 04066096	03-02-1992	San-Ei Kagaku Kogyo		Ab.
		JP 04066098	03-02-1992	San-Ei Kagaku Kogyo		Ab.
		JP 6014746	01-25-1994	Omiya Yakugyo; Ito Midori		Ab.

EXAMINER SIGNATURE _____ DATE CONSIDERED _____

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application No.	10/528,877
Filing Date	
First Named Inventor	Chang, Peter R.
Art Unit	
Examiner Name	

Sheet	2	01 00	4	Attorney Docket No.	10872/0527117
-------	---	----------	---	---------------------	---------------

		JP 6248267	09-06-1994	SII Techno Res Yugen; Nakayama Tsutomu		Ab.
		JP 07324037	12-12-1995	Nippon Getsuto		
		JP 9094077	04-08-1997	San Ei Gen FFI Inc.		Ab.
		DE 4107079	09-10-1992	Merck		Ab.
		DE 4339486	05-24-1995	Backhaus		Ab.
		DE 4340438	06-01-1995	Backhaus		Ab.
		SU 904709	02-15-1982	Sechnov, I.M. Medical Institute		Ab
		CN 1160048	09-24-1997	Peopl. Rep. China		Ab.
		CN 1217329	05-26-1999	Huo Xingling		Ab.

OTHER REFERENCES – NON PATENT LITERATURE DOCUMENTS

Examiner initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ⁶
		GRIFFITH, JR., J. et al., Effect of rutin on increased capillary fragility in man, Proc. Soc. Exptl. Biol. Med., 1944, vol. 55, pp 228-229	
		HUMPHREYS, F.R., The occurrence and industrial production of rutin in southeastern Australia, Economic Botany, 1964, vol. 18, 195-253	
		GRIFFITHS, L.A.. & BARROW, A., Metabolism of flavonoid compounds in germ-free rats, Biochem. J., 1972, vol. 130, pp 1161-1162	
		UYETA, M., et al., Mutagenicity of hydrolysates of tea infusions, Mutation Research, 1981, vol. 88, pp 233-240	
		BASARKAR, P.W. & NATH, N., Cholesterol lowering action of vitamin P-like compounds in rats, Indian Journal of Experimental Biology, Aug. 1981, vol. 19, pp 787-789	
		KATO, N., et al., Effects of dietary quercetin on serum lipids, Agric. Biol. Chem., 1983, vol. 47, no. 9, 2119-2120	
		PROCHAZKA, V., Can wild buckwheat be a commercial source, Naše Liečivé Rastliny, 1985, vol. 22, pt. 5, pp 131-133	
		MATSUBARA, Y., et al., Structure and Hypotensive Effect of Flavonoid Glycosides in <i>Citrus</i> <i>unshiu</i> peelings, Agric. Biol. chem., 1985, vol. 49, no. 4, pp 909-914	
		BORS, W., et al., [36] Flavonoids as antioxidants, Methods in Enzymology, 1990, vol. 186, pp 343-355, Academic Press	

EXAMINER SIGNATURE _____ DATE CONSIDERED _____

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application No.	10/528,877
Filing Date	
First Named Inventor	Chang, Peter R.
Art Unit	
Examiner Name	

Sheet	3	01 00	4	Attorney Docket No.	10872/0527117
-------	---	----------	---	---------------------	---------------

		HAYASHIBARA BIOCHEMICAL LABORATORIES INC., Water soluble rutin functioning as vitamin P, Japan Report Medical Technology, Feb. 1990, vol. 4, no. 2,	
		HAYASHIBARA BIOCHEMICAL LABORATORIES INC., Water soluble rutin, New Technology and Products, JETRO, Feb. 1990, p. 34	
		IWATA, K., et al., Effects of kangra buckwheat on spontaneously hypertensive rats, 1990, vol. 21, pp 55-61	
		YILDIZOĞLU-ARI, N., et al. Pharmacological effects of rutin, Phytotherapy Research, 1991, vol. 5, no. 1, pp 19-23	
		ABOU-KARAM, M. & SHIER, W., Isolation and characterization of an antiviral flavonoid from <i>Waldsteinia fragarioides</i> , Journal of Natural Products, Oct. 1992, vol. 55, no. 10, pp 1525-1527	
		DESCHNER, E., Dietary quercetin and rutin, inhibitors of experimental colonic neoplasia, Ch. 19, Phenolic Compounds in Food and Their Effects on Health II, 1992, ACS Symposium Series 507, American Chemical Society, Washington, DC	
		LUTTERODT, G.D. & ABU RAIHAN, S.M., Calcium modulation and antinociceptive efficacy of quercetin compounds, Asia Pacific Journal of Pharmacology, 1993, vol. 8, pp 127-131	
		AGULLO, G., et al., Quercetin exerts a preferential cytotoxic effect on active dividing colon carcinoma HT29 and Caco-2 cells, Cancer Letters, 1994, vol. 87, pp 55-63	
		MIDDLETON, JR., E. & KANDASWAMI, C, The impact of plant flavonoids on mammalian biology: implications for immunity, inflammation and cancer, The Flavonoids: Advances in Research Since 1986, Harborne, J.B., ed., 1994, Ch. 15, pp 619-652, Chapman & Hall, London	
		PISHA, E. & PEZZUTO, J., Fruits and vegetables containing compounds that demonstrate pharmacological activity in humans, Economic and Medicinal Plant Research, 1994, vol. 6, pp 189-233, Wagner & Farnsworth, ed., Academic Press, London	
		OOMAH, D & MAZZA, G., Flavonoids and antioxidative activities in buckwheat, J. Agri. Food Chem., 1996, vol. 44, no. 7, pp 1746-1750	
		MANACH, C., Bioavailability, metabolism and physiological impact of 4-oxo-flavonoids, Nutrition Research, 1996, vol. 16, no. 3, pp 517-544	
		FERRY, D., et al., Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for <i>in vivo</i> tyrosine kinase inhibition, Clinical Cancer Research, April 1996, vol. 2, pp 659-668	
		AGULLO, G., et al., Relationship between flavonoid structure and inhibition of phosphatidylinositol 3-kinase: a comparison with tyrosine kinase and protein kinase C inhibition, Biochemical Pharmacology, 1997, vol. 53, pp 1649-1657	
		WATANABE, J., et al., Isolation and identification of α -glucosidase inhibitors from tochu-cha (<i>Eucommia almoides</i>), Biosci. Biotech. Biochem., 1997, vol. 1, no. 1, pp 177-178	

EXAMINER SIGNATURE _____

DATE CONSIDERED _____

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application No.	10/528,877
Filing Date	
First Named Inventor	Chang, Peter R.
Art Unit	
Examiner Name	

Sheet	4	01 00	4	Attorney Docket No.	10872/0527117
-------	---	----------	---	---------------------	---------------

	MANACH, C., et al., Quercetin is recovered in human plasma as conjugated derivatives which retain antioxidant properties, FEBS Letters, 1998, vol. 426, pp 331-336	
	MINAMI, M., et al., Quantitative analysis of rutin in buckwheat (<i>Fagopyrum</i> sp.) by high performance liquid chromatography, Journal of the faculty of agriculture, 1998, vol. 34, no. 2, pp 91-95, Shinshu University, Minamiminowa, Nagano, Japan	
	MORAND, C., et al., Plasma metabolites of quercetin and their antioxidant properties, Am J. Physiol., 1998, vol. 275, pp R212-R219	
	NOROOZI, M., et al., Effects of flavonoids and vitamin C on oxidative DNA damage to human lymphocytes ¹⁻³ , Am. J. Clin. Nutr., 1998, vol. 67, pp 1210-1218	
	CRESPY, V., et al., Part of quercetin absorbed in the small intestine is conjugated and further secreted in the intestinal lumen, Am. J. Physiol. 1999, vol. 277, pp G120-G126	
	ASHIDA, H., et al., Flavones and flavonols at dietary levels inhibit a transformation of aryl hydrocarbon receptor induced by dioxin, FEBS Letters, 2000, vol. 476, pp 213-217	
	BORRELLI, F. & IZZO, A., The plant kingdom as a source of anti-ulcer remedies, Phytother. Res., 2000, vol. 14, pp 581-591	
	CALTAGIRONE, S., ET AL., Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential, Int. J. Cancer, 2000, vol. 87, 595-600	
	GEE, J., et al., Intestinal transport of quercetin glycosides in rats involves both deglycosylation and interaction with the hexose transport pathway, J. Nutri., 2000, vol. 130, pp 2765-2771	
	MORAND, C., et al., Quercetin 3-O- β -glucoside is better absorbed than other quercetin forms and is not present in rat plasma, Free Rad. Res., 2000, vol. 33, pp 667-676	
	SKIBOLA, C & SMITH, M., Potential health impacts of excessive flavonoid intake, Free Radical Biology & Medicine, 2000, vol. 29, nos. 3-4, pp 376-383	
	SLOLEY, B., et al., Chemical and pharmacological evaluation of <i>Hypericum perforatum</i> extracts, Acta Pharmacol Sin, Dec. 2000, vol. 21, no. 12, pp 1145-1152	
	WANG, H., The therapeutic potential of flavonoids, Exp. Opin. Invest. Drugs, 2000, vol. 9, no. 9, pp 2103-2119	
	YEŞİLADA, E., et al., Isolation and characterization of free radical scavenging flavonoid glycosides from the flowers of <i>Spartum junceum</i> by activity-guided fractionation, Journal of Ethnopharmacology, 2000, vol. 73, pp 471-478	
	ISHIGE, K., et al., Flavonoids protect neuronal cells from oxidative stress by three distinct mechanisms, Free Radical Biology & Medicine, 2001, vol. 30, no. 4, pp 433-446	
	VALERIO, L.G., et al., Induction of human NAD(P)H:quinone oxidoreductase (NQO1) gene expression by the flavonol quercetin, Toxicology Letters, 2001, vol. 119, pp 49-57	

EXAMINER SIGNATURE _____

DATE CONSIDERED _____

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.